PATENT CLAIM ANALYSIS

Application Number: 16108800
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["546", "153000"]

Abstract:
The present application provides deuterium-substituted quinoline derivatives, preparation methods thereof and uses thereof. In particular, the present application provides deuterium-substituted compounds of anlotinib, a tyrosine kinase inhibitor, and their preparation methods.

Claim (Index 15):
A method for determining the concentration of anlotinib in a sample, comprising using a compound of  claim 1  as an internal standard.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 96.0
- Lexical Diversity: 1.48
- Patent Class: 546.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13513982', '14211889', '15064895', '15809107', '13380693']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7635682474753412
- 35 USC 102 Novelty (BERT): 0.4998725209661651
- Combined Prediction Score: 0.7371986748244236
- Mean Citation Score: 195.492192
- Max Citation Score: 198.1763
- Similarity Product: 116.83406168667078

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test